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SCIENTIFIC EDITORIAL
Practical  management  of  heart  failure  with
preserved  ejection  fraction.  A  modest  proposal
Prise  en  charge  des  patients  en  insufﬁsance  cardiaque  à  fraction  d’éjection
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While  the  management  of  patients  with  cardiac  insufﬁciency  with  systolic  dysfunction  is
well  established  [1], that  of  cardiac  insufﬁciency  with  preserved  ejection  fraction  is  not
based  on  any  evidence.  This  is  why  —  even  though  this  pathology  is  present  in  more  than
50%  of  patients  with  heart  failure  in  clinical  practice  —  only  a  minimal  proportion  of  the
latest  European  guidelines  was  devoted  to  this  topic  (one-quarter  of  a  page  within  the  61
pages  of  recommendations  and  ﬁve  of  270  references  [1]).  It  also  notably  demonstrates
the  limits  of  the  recommendations  as  well  as  the  difﬁculty  in  writing  the  present  paper,
with  its  own  limitations  (it  is  a  personal  opinion  and  is  therefore  debatable).
The  treatment  philosophy  for  cardiac  insufﬁciency  with  preserved  systolic  function  is
completely  different  from  that  of  cardiac  insufﬁciency  with  altered  systolic  function:  with
the  latter,  you  want  to  block  hormonal  activation  (RAS,  sympathetic  system);  with  the
former  you  need  to  treat/address  the  causes  of  rigidity  in  the  arteries  and  cardiac  muscle
(e.g.  arterial  hypertension),  treat  all  comorbidities  that  could  aggravate  the  symptoms  of
cardiac  insufﬁciency,  such  as  anaemia  and  renal  insufﬁciency,  and  avoid  the  causes  of  acute
cardiac  decompensation  (e.g.  hypertensive  crisis,  infections,  sodium  overload,  tachycardic
episodes).  Finally  the  treatment  consists  of  maintaining  the  patient  in  euvolemia  (empha-
sizing  the  importance  of  therapeutic  education,  diuretic  treatment  as  a  base  if  needed,
avoiding  dehydration,  etc.),  as  outlined  in  Fig.  1.
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Figure 1. Proposed scheme for optimizing therapy in a patient with heart failure and preserved ejection fraction. ACEI: angiotensin
converting enzyme inhibitor; AF: atrial ﬁbrillation; BB: beta-blocker; BNP: brain natriuretic peptide; BP: blood pressure; Ca: calcium
antagonist; HF-PEF: heart failure with preserved ejection fraction; NSAI: non-steroidal anti-inﬂammatory agent; PM: pacemaker.
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dIn  the  absence  of  a  curative  treatment  for  cardiac  insuf-
ciency  with  preserved  systolic  function,  it  makes  sense
o  try  to  prevent  its  occurrence.  However,  in  order  to
o  so  it  is  important  to  understand  the  causes  of  or  fac-
ors  responsible  for  this  condition.  This  type  of  cardiac
nsufﬁciency  is  notably  observed  in  hypertensive  patients,
iabetic  patients,  the  elderly  and  in  patients  with  renal
nsufﬁciency  [2—4].  We  are  able  to  treat  diabetes  and  arte-
ial  hypertension  and  to  slow  the  progression  to  cardiac
nsufﬁciency  while  it  is  still  secondary  to  arterial  hyper-
ension  and  diabetes  [5].  The  correct  management  of  these
athologies  before  cardiac  insufﬁciency  occurs  is  therefore
undamental,  although  it  is  equally  important  after  cardiac
nsufﬁciency  appears  in  order  to  limit  its  progression  or  allow
or  a  possible  recovery  (e.g.  regression  of  cardiac  muscle
ypertrophy  after  stabilising  blood  pressure)  [6].
The  causal  role  played  by  arterial  hypertension  is
undamental:  it  is  a  factor  in  increasing  arterial  rigid-
ty,  cardiac  hypertrophy  and  renal  insufﬁciency.  Treating
f
m
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irterial  hypertension,  even  in  the  elderly,  allows  us  to  limit
he  appearance  of  cardiac  insufﬁciency.  The  Hypertension  in
he  Very  Elderly  Trial  (HYVET)  study,  for  example,  demon-
trated  that  the  treatment  of  systolic  arterial  hypertension
f  more  than  160  mmHg  in  patients  over  80  years  of  age
educes  the  risk  of  cardiac  insufﬁciency  by  60%  [7].
Even  after  the  development  of  cardiac  insufﬁciency,  the
reatment  of  arterial  hypertension  remains  of  utmost  impor-
ance.  This  treatment  is  often  challenging  to  put  in  place
nd  its  effects  are  difﬁcult  to  evaluate  due  to  the  vari-
bility  of  blood  pressure  levels  seen  in  such  patients:  the
igidity  of  their  arteries,  the  reduction  in  sensitivity  of
aroreceptors,  and  systolic  left  ventricular  function  beyond
he  normal  range  allow  rapid  variations  in  blood  pressure
epending  on  both  the  position  (orthostatic  hypotension  is
requent)  and  the  effort  being  exerted  (it  is  prudent  to
easure  ambulatory  arterial  pressure  in  these  patients  to
heck  that  blood  pressure  is  well  controlled).  The  possibil-
ty  of  stenosis  of  the  renal  arteries  should  be  considered
ion  f
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iPractical  management  of  heart  failure  with  preserved  eject
or  suspected  in  cases  of  persistent  hypertension,  the  treat-
ment  of  which  sometimes  results  in  stabilization  of  blood
pressure,  limits  the  progression  of  renal  insufﬁciency  and
avoids  the  recurrence  of  pulmonary  oedema,  often  sec-
ondary  to  a  rapid  increase  in  pressure  (i.e.  hypertensive
crisis)  [8].  The  choice  of  initial  treatment  for  the  manage-
ment  of  hypertension  is  often  determined  by  its  tolerance
[9]:  angiotensin-converting  enzyme  (ACE)  inhibitors  would
be  the  ﬁrst  option  in  patients  with  altered  renal  func-
tion  in  order  not  to  aggravate  the  condition;  calcium
channel  blockers  to  counteract  arterial  rigidity  (though
it  is  still  somewhat  unrealistic  to  hope  to  dilate  calci-
ﬁed  arteries);  beta-blockers  to  prevent  any  sudden  rises
in  blood  pressure  associated  with  stress;  and  diuretics  to
limit  or  reduce  hypervolemia,  which  is  often  present  due
to  renal  insufﬁciency  or  associated  nephroangiosclerosis.  In
practice,  our  preference  would  be  for  ACE  inhibitors  as  a
ﬁrst-line  treatment,  along  with  a  mild  diuretic  (thiazide)
and  a  beta-blocker  in  case  of  signiﬁcant  blood  pressure
lability.
Imagine that the arterial hypertension is
controlled
If  the  patient  is  in  atrial  ﬁbrillation  —  a  frequent  occurrence
in  this  group  of  often  hypertensive  elderly  patients  —  good
control  of  cardiac  rhythm  must  be  ensured.  Beta-blockers,
which  are  also  antihypertensive  drugs,  should  be  given  as
ﬁrst-line  treatment  because  they  control  both  resting  heart
rate  and  heart  rate  on  exertion,  which  digoxin  does  not
[1].  If  either  resting  heart  rate  or  heart  rate  on  exertion
remains  high  despite  high  doses  of  beta-blockers  (which  is
rare),  a  heart-rate-lowering  calcium  channel  blocker  (which
also  treats  arterial  hypertension)  could  also  be  given,  or
even  digoxin,  provided  renal  function  is  compatible  with
its  use.  Experience  shows  that  controlling  cardiac  rhythm
is  not  easy  to  achieve  in  these  patients,  who  often  arrive
as  emergencies  suffering  from  cardiac  decompensation.  If
there  is  any  doubt,  Holter  monitoring  should  be  carried  out
to  ensure  that  the  resting  heart  rate  as  measured  during  the
consultation  accurately  reﬂects  heart  rate  throughout  the
day.
The  problem  can  be  more  complex  in  patients  with  parox-
ysmal  atrial  ﬁbrillation,  who  may  have  the  beginning  of
bradycardia  or  tachycardia  syndrome.  Then,  bradycardia
may  occur  even  at  a  low  dose  of  beta-blockers,  insufﬁcient
to  lower  heart  rate  during  an  episode  of  atrial  ﬁbrillation.
These  atrial  ﬁbrillation  attacks  may  or  may  not  be  felt  in
the  form  of  palpitations,  and  are  therefore  easy  to  miss  if
the  clinician  does  not  check  carefully.  The  prescription  of
amiodarone  may  be  justiﬁed  to  avoid  such  attacks,  while
remaining  aware  of  the  risk  of  bradycardia  (and  the  risk  of
hyperthyroidism,  which  can  also  cause  decompensation  in
patients  with  cardiac  insufﬁciency  and  promote  atrial  ﬁbril-
lation).  If  the  episodes  of  atrial  ﬁbrillation  are  responsible
for  the  cardiac  decompensation  and  satisfactory  medical
treatment  cannot  be  given,  this  may  lead  us  to  propose  a
pacemaker,  allowing  the  introduction  of  a  satisfactory  anti-
tachycardic  treatment.  Even  paroxysmal  atrial  ﬁbrillation
justiﬁes  anticoagulant  treatment  [10].
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magine that the heart rate problem is
nder control
he  clinician  must  ensure  that  all  steps  have  been  taken  to
mprove  renal  function,  including  checking  for  the  use  of
nti-inﬂammatory  treatment,  which  is  sometimes  responsi-
le  for  episodes  of  cardiac  decompensation.  In  elderly  or
lder  individuals,  these  treatments  are  sometimes  consid-
red  indispensible  by  the  patients,  and  ﬁnding  an  alternative
an  be  very  challenging;  thus  it  is  often  better  to  leave
he  decision  to  the  rheumatologist.  . .  It  is  sometimes  nec-
ssary  to  accept  that  the  patient  will  not  always  behave  as
nstructed:  certain  patients  will  take  these  medications  irre-
pective  of  your  instructions,  at  least  from  time  to  time.  It
s  better  to  be  aware  of  their  use  to  be  able  to  anticipate
ardiac  decompensation  early.
Sometimes  the  opinion  of  a  nephrologist  is  useful,  when
enal  function  is  seriously  altered,  even  if  it  is  often  a
onsequence  of  hypertensive  nephroangiosclerosis  and/or
iabetic  nephropathy  for  which  nothing  can  be  done.  This
ype  of  renal  insufﬁciency  is  often  accompanied  by  hyper-
olemia  due  to  hyper-reninism  [11],  which  necessitates
iuretic  treatment  to  avoid  repeated  episodes  of  decompen-
ation.  Thus  in  these  patients,  even  in  the  absence  of  obvious
igns  of  congestion,  we  would  happily  prescribe  40  mg/day
f  furosemide  long-term,  certainly  in  cases  of  recurrent
ecompensation.  There  is  a  risk  of  excessive  diuretic  treat-
ent,  which  would  negatively  affect  renal  function;  as  this
ffect  is  purely  functional  it  would  regress  upon  discontinu-
tion  of  the  treatment.  If  renal  function  worsens,  reducing
he  dosage  of  diuretics,  in  the  absence  of  any  signs  of
ongestion,  would  be  or  is  justiﬁed.
The  patient  now  has  normal  arterial  tension,  with  no
pisodes  of  tachycardia,  with  diuretic  treatment  in  case  of
ephroangiosclerosis  with  renal  insufﬁciency.  If  this  sufﬁces
o  treat  the  cardiac  insufﬁciency  and  the  patient  does  not
uffer  any  episodes  of  acute  heart  failure  whilst  taking  the
edication,  the  therapeutic  process  would  end  there  until
he  next  eventual  episode  of  acute  heart  failure.  Everything
ust  be  done  to  avoid  factors  favouring  decompensation:
he  role  played  by  pulmonary  infections  justiﬁes  vaccination
gainst  inﬂuenza;  we  have  already  addressed  the  problem
f  anti-inﬂammatory  treatment.
Anaemia  has  a  speciﬁc  role:  it  is  a potential  cause  of
ecompensation,  which  must  be  carefully  looked  for,  and
hich  should  lead  to  a  thorough  examination  to  ﬁnd  the
ause  when  present  [12,13]. Iron  supplementation,  possibly
ntravenous,  should  be  prescribed  if  needed,  if  no  source  of
leeding  is  found.
Finally,  diuretic  treatment,  which  is  generally  based  on
urosemide,  should  be  adapted  to  the  blood  volume  of  the
atient.  Antialdosterones  (now  referred  to  as  mineralocor-
icoid  receptor  antagonists)  should  be  used  with  extreme
aution  in  elderly  patients  and  are  contraindicated  in  cases
f  renal  insufﬁciency  [14].
Patient  monitoring  should  allow  acute  episodes  of  renal
nsufﬁciency  to  be  avoided,  notably  during  extreme  weather,
uch  as  heat  waves  where  temperatures  vary  greatly.  In
ffect,  patients  receiving  diuretic  treatment  lose  some  of
heir  capacity  to  adapt  their  blood  volume,  and  are  partic-
larly  susceptible  to  left  ventricular  preload  due  to  arterial
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nd  ventricular  rigidity,  and  thus  are  easily  susceptible  to
ypovolemia  during  a  heat  wave,  with  renal  insufﬁciency,
yperkalemia,  etc.  Conversely,  due  to  the  rigidity  of  the
eft  ventricle,  they  can  also  quickly  become  hypervolemic
fter  the  sudden  absorption  of  an  excessive  quantity  of  salt.
herapeutic  education,  which  is  part  of  the  treatment  of  all
atients  with  cardiac  insufﬁciency,  is  particularly  important
ere  (and  is  difﬁcult  in  elderly  patients),  in  those  patients
or  whom  management  of  blood  volume  is  the  main  part  of
heir  symptom  treatment  but  also  their  preventive  treat-
ent  against  decompensation.  Exercise  may  also  be  useful
15].
Patients  with  cardiac  insufﬁciency  with  preserved  ejec-
ion  fraction  are  often  elderly,  and  are  unable  to  beneﬁt
rom  individualized  monitoring  of  B-type  or  Nt-B-type  natri-
retic  peptide,  possibly  because  the  best  response  to  initial
ecompensation  is  not  the  same  for  all  patients  and  thus
annot  be  standardized.  Monitoring  and  follow-up  are  there-
ore  both  clinical  and  biological  with  repetition  of  blood
lectrolyte  tests  and  blood  creatinine  and  urea  levels  when
here  is  a  risk  of  decompensation.
In  conclusion,  the  therapeutic  approach  to  a patient
ho  presents  with  cardiac  insufﬁciency  with  preserved  ejec-
ion  fraction  is  much  more  individualized  than  the  standard
reatment  for  patients  with  cardiac  insufﬁciency  and  altered
jection  fraction.  This  population  is  more  heterogeneous,
he  causes  for  heart  failure  are  different,  etc.  This  is  the
omain  of  non-evidence-based  medicine,  which  will  always
xist!
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